DK1711481T4 - Krystallinsk monohydrat som kinaseinhibitorer - Google Patents

Krystallinsk monohydrat som kinaseinhibitorer

Info

Publication number
DK1711481T4
DK1711481T4 DK05722772.0T DK05722772T DK1711481T4 DK 1711481 T4 DK1711481 T4 DK 1711481T4 DK 05722772 T DK05722772 T DK 05722772T DK 1711481 T4 DK1711481 T4 DK 1711481T4
Authority
DK
Denmark
Prior art keywords
kinase inhibitors
crystalline monohydrate
monohydrate
crystalline
kinase
Prior art date
Application number
DK05722772.0T
Other languages
Danish (da)
English (en)
Other versions
DK1711481T3 (da
Inventor
Bang-Chi Chen
Roberto Droghini
Jean Lajeunesse
John D Dimarco
Michael Galella
Ramakrishnan Chidambaram
Original Assignee
Brystol Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34864498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1711481(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brystol Myers Squibb Company filed Critical Brystol Myers Squibb Company
Application granted granted Critical
Publication of DK1711481T3 publication Critical patent/DK1711481T3/da
Publication of DK1711481T4 publication Critical patent/DK1711481T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK05722772.0T 2004-02-06 2005-02-04 Krystallinsk monohydrat som kinaseinhibitorer DK1711481T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54249004P 2004-02-06 2004-02-06
US62493704P 2004-11-04 2004-11-04
PCT/US2005/003728 WO2005077945A2 (en) 2004-02-06 2005-02-04 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors

Publications (2)

Publication Number Publication Date
DK1711481T3 DK1711481T3 (da) 2010-04-19
DK1711481T4 true DK1711481T4 (da) 2013-08-26

Family

ID=34864498

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05722772.0T DK1711481T4 (da) 2004-02-06 2005-02-04 Krystallinsk monohydrat som kinaseinhibitorer

Country Status (26)

Country Link
EP (1) EP1711481B2 (enExample)
JP (2) JP5148115B2 (enExample)
KR (2) KR101310427B1 (enExample)
AR (1) AR047533A1 (enExample)
AT (1) ATE453630T1 (enExample)
AU (1) AU2005212405B2 (enExample)
BR (1) BRPI0507476B8 (enExample)
CA (1) CA2555291C (enExample)
CY (1) CY1109907T1 (enExample)
DE (1) DE602005018601D1 (enExample)
DK (1) DK1711481T4 (enExample)
ES (1) ES2337272T5 (enExample)
GE (1) GEP20094804B (enExample)
HR (1) HRP20100166T4 (enExample)
IL (1) IL177280A (enExample)
IN (1) IN2014DN06567A (enExample)
NO (1) NO338049B1 (enExample)
NZ (1) NZ548613A (enExample)
PE (1) PE20050691A1 (enExample)
PL (1) PL1711481T5 (enExample)
PT (1) PT1711481E (enExample)
RU (1) RU2382039C2 (enExample)
SI (1) SI1711481T2 (enExample)
TW (1) TWI338004B (enExample)
WO (1) WO2005077945A2 (enExample)
ZA (1) ZA200606242B (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450777C (en) 2001-08-10 2013-04-09 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
BRPI0409949A (pt) 2003-05-01 2006-04-25 Bristol Myers Squibb Co compostos de pirazol amida aril-substituìda úteis como inibidores de cinase
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TW200600513A (en) 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
WO2006121742A2 (en) * 2005-05-05 2006-11-16 Bristol-Myers Squibb Company Formulations of a src/abl inhibitor
EP1919885B1 (en) * 2005-08-05 2010-04-28 Brystol-Myers Squibb Company Preparation of 2-amino-thiazole-5-carboxylic-acid derivatives
EP1937270A1 (en) * 2005-09-21 2008-07-02 Brystol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
US20070219370A1 (en) * 2006-03-15 2007-09-20 Bristol-Myers Squibb Company Process for preparing n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino] -5-thiazolecarboxamide and related metabolites thereof
US7888361B2 (en) 2006-09-11 2011-02-15 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
ES2565521T5 (es) 2007-10-23 2019-12-10 Teva Pharma Polimorfos de dasatinib y proceso para la preparación de los mismos
WO2010062715A2 (en) * 2008-11-03 2010-06-03 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010067374A2 (en) * 2008-12-08 2010-06-17 Hetero Research Foundation Polymorphs of dasatinib
WO2010129208A1 (en) * 2009-05-05 2010-11-11 Merck Sharp & Dohme Corp. P38 kinase inhibiting agents
CN101812060B (zh) * 2010-02-02 2011-08-17 南京卡文迪许生物工程技术有限公司 一种简捷制备高纯度达沙替尼的新方法以及中间体化合物
EP2359813A1 (en) 2010-02-04 2011-08-24 Ratiopharm GmbH Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
CN102250084A (zh) * 2010-02-08 2011-11-23 南京卡文迪许生物工程技术有限公司 达沙替尼多晶型物及其制备方法和药用组合物
JP5589097B2 (ja) * 2010-02-08 2014-09-10 南京▲か▼文迪許生物工程技術有限公司 ダサチニブ多結晶体、並びにその調製方法及び薬物組成物
WO2013065063A1 (en) 2011-11-03 2013-05-10 Cadila Healthcare Limited Anhydrous form of dasatinib, process for its preparation and its use
CA2876539A1 (en) * 2012-06-15 2013-12-19 Basf Se Multicomponent crystals comprising dasatinib and selected co-crystal formers
CN102827156A (zh) * 2012-09-11 2012-12-19 湖南欧亚生物有限公司 一种达沙替尼的新的工业合成方法
CN103819469A (zh) * 2012-11-16 2014-05-28 重庆医药工业研究院有限责任公司 一种达沙替尼的晶型及其制备方法
CZ306598B6 (cs) 2012-12-06 2017-03-22 Zentiva, K.S. Způsob přípravy a čištění nových i známých polymorfů a solvátů dasatinibu
CN103880833B (zh) * 2012-12-19 2018-04-06 北京本草天源药物研究院 达沙替尼一水合物的新晶形及其制备方法和药物组合物
WO2014102759A2 (en) 2012-12-31 2014-07-03 Ranbaxy Laboratories Limited Process for the preparation of dasatinib and its intermediates
CN103319476B (zh) * 2013-06-13 2015-12-02 济南德爱医药技术有限公司 一种激酶抑制剂
US9884857B2 (en) 2013-07-25 2018-02-06 Basf Se Salts of dasatinib in amorphous form
CA2917183C (en) * 2013-07-25 2019-01-29 Basf Se Salts of dasatinib in crystalline form
CN104341410A (zh) * 2013-08-09 2015-02-11 上海科胜药物研发有限公司 一种达沙替尼新晶型及其制备方法
CN103483289B (zh) * 2013-09-06 2016-01-27 浙江科源化工有限公司 一种2-氨基-n-(2-氯-6-甲基苯基)噻唑-5-甲酰胺的合成方法
IN2013MU03610A (enExample) 2013-12-18 2015-04-24 Dharmesh Mahendrabhai Shah
CZ306732B6 (cs) * 2013-12-19 2017-05-31 Zentiva, K.S. Způsob přípravy bezvodé polymorfní formy N-6 Dasatinibu
CA2882438A1 (en) 2014-03-11 2015-09-11 Cerbios-Pharma Sa Process and intermediates for the preparation of dasatinib
RU2567537C1 (ru) * 2014-04-23 2015-11-10 Олег Ростиславович Михайлов Кристаллическая безводная дельта-модификация n-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамида, способ ее получения и фармацевтическая композиция на ее основе
HU231013B1 (hu) * 2014-05-26 2019-11-28 Egis Gyógyszergyár Zrt. Dasatinib sók
US10301302B2 (en) 2015-06-29 2019-05-28 Msn Laboratories Private Limited Crystalline forms of N-(2-chloro-6-methy]phenvn-2-[F6-[4-(2-hvdroxvethvl)-L-piperazin-vil-2-methvil-4-pvrimidinvllaminol-5-thiazolecarboxamide and their process thereof
WO2017098391A1 (en) * 2015-12-11 2017-06-15 Shilpa Medicare Limited Process for the preparation of dasatinib
WO2017108605A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous dasatinib
CN105503854A (zh) * 2015-12-31 2016-04-20 哈药集团技术中心 一种达沙替尼无水合物的新晶型物及其制备方法
JP2019504090A (ja) 2016-02-03 2019-02-14 ドクター レディズ ラボラトリーズ リミテッド ダサチニブの固体状態形態およびそれらの調製プロセス
WO2017144109A1 (en) 2016-02-25 2017-08-31 Remedica Ltd Dasatinib formulation
GB201608587D0 (en) 2016-05-16 2016-06-29 Univ Dundee Treatment of opiod tolerance
CN106117195A (zh) * 2016-06-09 2016-11-16 青岛辰达生物科技有限公司 一种用于治疗白血病的药物达沙替尼的合成方法
IT201700006145A1 (it) 2017-01-20 2018-07-20 Cerbios Pharma Sa Co-cristallo di un composto antitumorale
IT201700006157A1 (it) * 2017-01-20 2018-07-20 Cerbios Pharma Sa Co-cristalli di un composto antitumorale
JP6597727B2 (ja) 2017-05-11 2019-10-30 東洋インキＳｃホールディングス株式会社 表面保護用粘着剤および粘着シート
CN111108104A (zh) * 2017-07-07 2020-05-05 拜康有限公司 达沙替尼的多晶形式
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN111601593B (zh) 2017-10-05 2022-04-15 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
KR20210042896A (ko) 2018-06-15 2021-04-20 한다 파마슈티칼스, 인코포레이티드 카이네이스 억제제 염 및 이의 조성물
DK3643713T3 (da) 2018-10-23 2025-11-03 Iomx Therapeutics Ag Heterocykliske kinaseinhibitorer og deres anvendelse
CN109369638B (zh) * 2018-11-21 2020-07-07 山东罗欣药业集团股份有限公司 一种达沙替尼的制备工艺
CN109503568B (zh) * 2018-12-29 2020-08-07 山东罗欣药业集团股份有限公司 一种达沙替尼的制备方法
WO2021028518A1 (de) * 2019-08-15 2021-02-18 Bayer Aktiengesellschaft Verfahren zur herstellung von 2-(phenylimino)-3-alkyl-1,3-thiazolidin-4-onen
CN112409349A (zh) * 2019-08-20 2021-02-26 湖南华纳大药厂股份有限公司 激酶抑制剂及其制备、药物组合物和用途
AU2021210974A1 (en) 2020-01-24 2022-09-22 Handa Therapeutics, Llc Amorphous solid dispersions of dasatinib and uses thereof
GB2592680A (en) 2020-03-06 2021-09-08 Zentiva Ks Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof
EP4071248A1 (en) 2021-04-07 2022-10-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Means and methods for enhancing receptor-targeted gene transfer
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
CN114634421A (zh) * 2022-02-24 2022-06-17 济宁晟泰药业有限公司 一种达沙替尼中间体的制备方法
TW202523302A (zh) 2023-11-02 2025-06-16 美商阿克思生物科學有限公司 噻唑化合物及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505055A (en) * 1966-12-07 1970-04-07 Uniroyal Inc Method of controlling plant growth with carboxamidothiazoles
US5514643A (en) * 1993-08-16 1996-05-07 Lucky Ltd. 2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms
ID24231A (id) * 1997-06-24 2000-07-13 Janssen Pharmaceutica Nv Derivat-derivat 5-disubstitusi-1,2,4-tiadiazolil yang menghambat angiogenesis
CN101481359A (zh) * 1999-04-15 2009-07-15 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
WO2004071440A2 (en) * 2003-02-06 2004-08-26 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
EP2233174B1 (en) * 2004-01-21 2016-07-20 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors

Also Published As

Publication number Publication date
SI1711481T2 (sl) 2013-10-30
SI1711481T1 (sl) 2010-03-31
EP1711481B2 (en) 2013-05-22
IL177280A (en) 2013-09-30
BRPI0507476B8 (pt) 2021-05-25
PL1711481T3 (pl) 2010-05-31
WO2005077945A2 (en) 2005-08-25
KR101310427B1 (ko) 2013-09-24
KR20060124692A (ko) 2006-12-05
DE602005018601D1 (de) 2010-02-11
EP1711481B1 (en) 2009-12-30
HRP20100166T1 (hr) 2010-05-31
EP1711481A2 (en) 2006-10-18
PE20050691A1 (es) 2005-09-25
GEP20094804B (en) 2009-10-26
KR20120097424A (ko) 2012-09-03
DK1711481T3 (da) 2010-04-19
NZ548613A (en) 2010-05-28
PT1711481E (pt) 2010-02-25
HK1091835A1 (zh) 2007-01-26
ATE453630T1 (de) 2010-01-15
CY1109907T1 (el) 2014-09-10
IL177280A0 (en) 2006-12-10
IN2014DN06567A (enExample) 2015-07-10
PL1711481T5 (pl) 2013-10-31
CA2555291A1 (en) 2005-08-25
JP5148115B2 (ja) 2013-02-20
AU2005212405A1 (en) 2005-08-25
WO2005077945A3 (en) 2006-05-18
RU2006131591A (ru) 2008-03-20
JP2007521340A (ja) 2007-08-02
CA2555291C (en) 2017-01-17
NO20063780L (no) 2006-10-27
NO338049B1 (no) 2016-07-25
ES2337272T3 (es) 2010-04-22
ES2337272T5 (es) 2013-09-30
JP2012188446A (ja) 2012-10-04
BRPI0507476B1 (pt) 2020-12-08
BRPI0507476A (pt) 2007-07-17
AU2005212405B2 (en) 2010-08-12
RU2382039C2 (ru) 2010-02-20
ZA200606242B (en) 2008-01-08
TWI338004B (en) 2011-03-01
HRP20100166T4 (en) 2013-09-30
TW200530205A (en) 2005-09-16
AR047533A1 (es) 2006-01-25

Similar Documents

Publication Publication Date Title
DK1711481T4 (da) Krystallinsk monohydrat som kinaseinhibitorer
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1585749T3 (da) Diazepinoindol-derivater som kinaseinhibitorer
NO20082517L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK1761505T3 (da) Pyrimidin-urinstof-derivater som kinaseinhibitorer
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
DK1910333T3 (da) Piperidinylsubstituerede isoquinolonderivater som RHO-kinaseinhibitorer
DK1959951T3 (da) Heteroaryl-substituerede piperidinderivater som L-CPT1-inhibitorer
CY2016045I2 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
DK1720882T3 (da) Pyrazolopyrimidin-derivater som cyclin-afhængige kinaseinhibitorer
DK1881976T3 (da) Substituerede amidderivater som proteinkinaseinhibitorer
DK1699797T3 (da) Pyrrolotriazinforbindelser som kinasehæmmere
IL184674A0 (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
DK1586319T3 (da) Thiadiazolidinoner som GSK-3-inhibitorer
DK1704145T3 (da) Selektive kinaseinhibitorer
DK1984350T3 (da) Pyrimidinderivater anvendt som PI-3-kinaseinhibitorer
EP1951684A4 (en) BIARYLMETAPYRIMIDINKINASEINHIBITOREN
DK2094263T3 (da) 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
DK2220070T3 (da) 2-benzylpyridazinonderivater som Met-kinaseinhibitorer
DK1778686T3 (da) Triazolopyridinylsulfanylderivater som P38 MAP kinase-inhibitorer
DK1660090T3 (da) Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
DK1763517T3 (da) Pyrimidinderivater som 11beta-HSD1-inhibitorer
DK1937671T3 (da) Benzimidazolthiophenforbindelser som PLK-inhibitorer
DK1740569T3 (da) Imidazol-derivater som TAFla-inhibitorer